The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Peer Reviewed Cancer Research Program (PRCRP) -- Translational Team Science Award
The FY20 PRCRP Translational Team Science Award (TTSA) supports hypothesis-driven translational studies. These studies should be associated with clinical trial. The proposed project should focus on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that are based on results from clinical investigations. While funding for clinical trials is allowed, the TTSA is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or investigate novel clinical findings.
The FY20 PRCRP TTSA Areas of Emphasis (strongly encouraged but not required):
• Interventions to improve quality of life for cancer patients and/or survivors
• Cancer prevention or early detection
Applications proposing a study not within the scope of the FY20 PRCRP TTSA Areas of Emphasis must demonstrate that the research proposed once translated to the clinic will have lasting impact in the research area studies.
• Required Pre-Application Deadline: July 30, 2020
• Application Submission Deadline: August 27, 2020
Areas of Interest
To be considered for funding, applications for the FY20 PRCRP Translational Team Science Award must address at least one of the FY20 PRCRP Topic Areas as directed by Congress. Congressional language for the FY20 PRCRP provides funds for research into cancers not addressed in the breast, kidney, lung, pancreatic, prostate, ovarian, rare cancer, and melanoma research programs. Research applications in the areas of breast, kidney, lung (excluding mesothelioma), prostate, pancreatic, rare cancer, ovarian cancer or melanoma will not be accepted. The inclusion of the individual Rare Cancer Research Program shall not prohibit the PRCRP from funding the below mentioned cancers or cancer subtypes that may be rare by definition. The FY20 PRCRP Topic Areas are listed below.
• Bladder cancer • Blood cancers • Brain cancer • Colorectal cancer • New for FY20: Esophageal cancer • New for FY20: Head and Neck cancer • Immunotherapy1 • Liver cancer • Mesothelioma • New for FY20: Metastatic cancers • Neuroblastoma • Pediatric brain tumors • Pediatric, adolescent, and young adult cancers2 • Stomach cancer
For research funded under the FY20 PRCRP Topic Area metastatic cancers research proposed must be targeted to cancer that has spread from its original location to another place in the body, representing what is known as stage III and stage IV cancer diagnoses. While recent research has revealed that there is a genetic basis for susceptibility or resistance to metastasis, more research is needed to develop a comprehensive understanding of this complex process. Applications to the metastatic cancer topic area should focus on the process of metastasis and not the cancer type (i.e.an agnostic interrogation of the process of metastasis).All research funded under the FY20 PRCRP must follow Congressional language (i.e., prohibited cancers).
The investigator named as the Initiating PI on the application must be at or above the level of Assistant Professor or equivalent. The investigator(s) named as the Partnering PI(s) on the application must be at or above the level of Assistant Professor or equivalent. Postdoctoral fellows are not eligible to be Initiating or Partnering PIs. It is encouraged that at least one of the PIs be a military or VA investigator.
The anticipated direct costs budgeted for the entire period of performance for an FY20 PRCRP TTSA] award will not exceed $1,500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.